Relmada Therapeutics Files 8-K: Material Agreement and Disclosures
Ticker: RLMD · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1553643
| Field | Detail |
|---|---|
| Company | Relmada Therapeutics, Inc. (RLMD) |
| Form Type | 8-K |
| Filed Date | Feb 6, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, regulatory-disclosure, corporate-events
TL;DR
Relmada signed a big deal and filed some important stuff. Check the details.
AI Summary
On February 3, 2025, Relmada Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other events. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for Relmada Therapeutics, including a new material agreement and regulatory disclosures that could impact investors.
Risk Assessment
Risk Level: medium — Material definitive agreements and regulatory disclosures can signal significant business changes, potentially impacting the company's stock price and future prospects.
Key Players & Entities
- Relmada Therapeutics, Inc. (company) — Registrant
- February 3, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 001-39082 (identifier) — Commission File Number
- 45-5401931 (identifier) — IRS Employer Identification No.
- 2222 Ponce de Leon Blvd. (address) — Principal executive offices
- Coral Gables, FL 33134 (address) — Principal executive offices
FAQ
What type of material definitive agreement did Relmada Therapeutics enter into?
The filing states that Relmada Therapeutics, Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 3, 2025.
In which state was Relmada Therapeutics, Inc. incorporated?
Relmada Therapeutics, Inc. was incorporated in Nevada.
What is the Commission File Number for Relmada Therapeutics, Inc.?
The Commission File Number for Relmada Therapeutics, Inc. is 001-39082.
What are the principal executive offices of Relmada Therapeutics, Inc.?
The principal executive offices of Relmada Therapeutics, Inc. are located at 2222 Ponce de Leon Blvd., Floor 3, Coral Gables, FL 33134.
Filing Stats: 1,056 words · 4 min read · ~4 pages · Grade level 12.8 · Accepted 2025-02-06 06:38:57
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share RLMD The Nasdaq
- $250,000 — e Agreement, which includes a credit of $250,000 for a previous payment made by the Comp
Filing Documents
- ea0230164-8k_relmada.htm (8-K) — 44KB
- ea023016401ex10-1_relmada.htm (EX-10.1) — 97KB
- ea023016401ex99-1_relmada.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 5KB
- 0001213900-25-010711.txt ( ) — 369KB
- rlmd-20250203.xsd (EX-101.SCH) — 3KB
- rlmd-20250203_lab.xml (EX-101.LAB) — 33KB
- rlmd-20250203_pre.xml (EX-101.PRE) — 22KB
- ea0230164-8k_relmada_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 6, 2025 RELMADA THERAPEUTICS, INC. By: /s/ Sergio Traversa Name: Sergio Traversa Title: Chief Executive Officer 3